Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Non-Hodgkin 37Lymphoma 37Lymphoma, Follicular 33Lymphoma, Large B-Cell, Diffuse 30Lymphoma, Mantle-Cell 22Lymphoma, B-Cell, Marginal Zone 13Leukemia, Lymphocytic, Chronic, B-Cell 13Waldenstrom Macroglobulinemia 9Lymphoma, Large-Cell, Immunoblastic 9Burkitt Lymphoma 9Lymphoma, B-Cell 6Lymphoma, Large-Cell, Anaplastic 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 2Leukemia 2Recurrence 1Orbital lymphoma 1Oncology Patients Receiving Chemotherapy 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, AIDS-Related 1Lymphatic Diseases 1Immunoproliferative Disorders 1Immune System Diseases 1Graft vs Host Disease 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Dexamethasone 111Cyclophosphamide 99Melphalan 91Bortezomib 69Peripheral Blood Stem Cell Transplantation 64Lenalidomide 58fludarabine phosphate 56Busulfan 54Filgrastim 50Tacrolimus 38Antilymphocyte Serum 38Thalidomide 36Radiotherapy 36Mycophenolic Acid 33fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Whole-Body Irradiation 21Prednisone 21Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 15Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × ibritumomab tiuxetan × Clear all
NCT00477815 2018-05-14

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Mayo Clinic

Phase 1 Completed
30 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡